Ixoreal Biomed highlights an exploratory placebo-controlled study of SRI-81 Shatavari, alone and combined with KSM-66 Ashwagandha, published in the International Journal of Women’s Health.
News|Articles|May 29, 2026
Emerging Science and Market Trends in Bone and Joint Nutrition
Author(s)Gelita
Martin Walter explores the evolving science of musculoskeletal wellness, from collagen’s foundational role in bone and cartilage health to the innovative formulation strategies shaping the next generation of supplements. As demographic shifts and a growing focus on proactive, preventive health expand the bone and joint category beyond traditional calcium and vitamin D, clinically supported collagen peptides are opening new possibilities in this fast-growing market.
Advertisement
Learn More About:
- The key demographic and lifestyle trends driving growth in the bone and joint health supplement market
- How bioactive collagen peptides support bone mineral density, cartilage integrity, and joint mobility
- Formulation approaches that are redefining musculoskeletal health products, including synergistic ingredient combinations and emerging delivery formats
Advertisement
Related to this article
Clinical research moves beyond compliance, focusing on smarter trial design, risk-based quality, and “evidence engineering” to deliver decisive, decision-ready results.
The company says the innovation, built on its CoreNhanced BioJourney platform, is designed for beverage and gummy formats.
AuraFen, BILVORA, and IMBE debut at SupplySide Global 2026, and the company will also highlight its CaFi digestive health ingredient.
Horphag Research's Sébastien Bornet breaks down the clinical science behind Robuvit, exploring how the caffeine-free French oak extract supports mitochondrial energy, mood stability, and stress resilience.
Todd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules while advocating for federal uniformity.
FDA's final NDI guidance sets identity and safety expectations. See what AHPA and CRN say remains unresolved and what it means for suppliers.
The company plans to present Organicaps capsules in size 0, 25 years of UC-II, and liquid-filled capsule technology.
Advertisement
Advertisement
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
Navigating Supplement Ingredients and Claims Regulations in Europe, the US, and Canada
2
FDA Finalizes NDI Guidance on Identity and Safety Information, Leaving Some Industry Concerns Open
3
Thirty Years of GCP: The Evolution From Study Execution to Evidence Generation
4
CoreFX Launches CreaSHLD-IN Shielded Creatine at SupplySide Global 2026
5